Mersana Therapeutics, Inc. (NASDAQ: MRSN) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT MERSANA THERAPEUTICS, INC.

Mersana Therapeutics, Inc. (NASDAQ: MRSN)
Listen to this Section


$0.71
+0.1080 ( +17.00% ) 4.5M

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Market Data


Open $0.71
Previous Close $0.61
Volume 4.5M
Market Cap $74.74M
Day Range $0.61 - $0.72
52 Week Range $0.49 - $6.28
Shares Outstanding 123.53M
Change % +17.00%
Net Change ▲ 0.1080
Insider Ownership -0.85%
Exchange NASDAQ
Sector Miscellaneous
Industry None
IPO Year 2017
Country United States
Under Writer IPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -2,022,985.00

Date Type Amount Purchased Purchaser
2024-07-02 Sale -8972.00 Alleva Lawrence M
2024-06-12 Sale -55000.00 Hack Andrew A. F.
2024-06-12 Sale -55000.00 Hege Kristen
2024-06-12 Sale -55000.00 MOTT DAVID M
2024-06-12 Sale -55000.00 Dere Willard H
2024-06-12 Sale -55000.00 Alleva Lawrence M
2024-06-12 Sale -55000.00 Diaz Allene M.
2024-06-12 Sale -55000.00 Protopapas Anna
2024-04-03 Sale -3996.00 Alleva Lawrence M
2024-01-17 Sale -9375.00 Lowinger Timothy B

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 14 May 09, 2024
10-q Quarterly Reports 70 May 09, 2024
ars Annual reports 1 Apr 26, 2024
def Proxies and info statements 9 Apr 26, 2024
4 Insider transactions 1 Apr 03, 2024
8-k 8K-related 19 Feb 28, 2024
10-k Annual reports 113 Feb 28, 2024
8-k 8K-related 15 Feb 28, 2024
4/a Other 1 Feb 16, 2024

Latest News


× Before browsing our site, please accept our cookies policy